Creagene to conduct phase 1 study of novel rheumatoid arthritis treatment
Published: 2010-06-15 06:56:00
Updated: 2010-06-15 06:56:00
Creagene, a subsidiary of Choong-wae Pharm, said on June 11 that it will conduct Creavax-RA injection, a rheumatoid arthritis treatment using immunoregulation dendritic cells sooner or later after its approval from the Korea Food and Drug Administration.
A spokesman at Creagene stated “Creagen...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
